From: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers
Characteristics | No. (%) |
---|---|
No. of patients | 519 |
Median age, years (range) | 64 (18–92) |
Sex | |
 Male | 300 (57.8) |
 Female | 219 (42.2) |
Cancer type | |
 Bladder cancer | 27 (5.2) |
 Esophagogastric cancer | 40 (7.7) |
 Head and neck cancer | 10 (1.9) |
 Melanoma | 148 (28.5) |
 Non-small-cell lung cancer | 294 (56.6) |
Drug class | |
 CTLA-4, monotherapy | 142 (27.4) |
 PD-(L)1, monotherapy | 320 (61.7) |
 CTLA-4 + PD-(L)1, combination therapy | 57 (11.0) |
Best overall response | |
 CR/PR | 126 (24.3) |
 SD | 137 (26.4) |
 PD | 252 (48.6) |
 NE | 4 (0.8) |
Durable clinical benefit | |
 DCB | 165 (31.8) |
 NDB | 330 (63.6) |
 NE | 24 (4.6) |
Median TMB, Mutation/Mb (IQR) | 7.14 (3.77–13.24) |
TET1 status | |
 Mutant | 23 (4.4) |
 Wildtype | 496 (95.6) |